ADT Not Needed With Radiation in Favorable Intermediate-Risk PC

ADT Not Needed With Radiation in Favorable Intermediate-Risk PC
Adding four months of androgen deprivation therapy (ADT) to radiation treatment extends survival and delays metastasis in men with unfavorable intermediate-risk prostate cancer, according to a secondary analysis of a Phase 3 clinical trial. However, that new trial analysis showed there were no such benefits to ADT therapy for men with favorable intermediate-risk prostate cancer undergoing radiation therapy. These findings support the National Comprehensive Cancer Network recommendations that ADT treatment only be given to patients with unfavorable intermediate-risk prostate cancer. The study,” Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable,
Subscribe or to access all post and page content.